RLAY - Dividend announcements

Announced RLY-4008 interim clinical data that suggest it is the first investigational therapy that selectively binds to FGFR2 and avoids off-isoform toxicities in the treatment of patients with FGFR2-altered tumors Shared preclinical data for RLY-2608, the first known allosteric, pan-mutant and isoform-selective PI3Kα inhibitor and dosed the first patient in a first-in-human trial Continued to advance three additional oncology preclinical programs and two genetic disease preclinical programs, while expanding the capabilities of the Dynamo™ platform Raised $382 million in net proceeds from a follow-on financing in October 2021 $958 million in cash, cash equivalents and inv

Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3Kα mutant selective inhibitor in 2021 Entered into a global collaboration with Genentech for the development and commercialization of RLY-1971 Continued to advance three additional oncology preclinical programs and extended work outside of oncology into genetic diseases with two preclinical programs $678.1 million in cash, cash equivalents and marketable securities at end of 2020, with the $75 million upfront payment received from Genentech in 2021, expected to fund operations into 2024 CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics,